Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Stability and inactivation of SARS coronavirus

Identifieur interne : 000428 ( Pmc/Curation ); précédent : 000427; suivant : 000429

Stability and inactivation of SARS coronavirus

Auteurs : H. F. Rabenau [Allemagne] ; J. Cinatl [Allemagne] ; B. Morgenstern [Allemagne] ; G. Bauer [Allemagne] ; W. Preiser [Allemagne] ; H. W. Doerr [Allemagne]

Source :

RBID : PMC:7086689

Abstract

The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56°C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60°C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agent’s tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene.


Url:
DOI: 10.1007/s00430-004-0219-0
PubMed: 15118911
PubMed Central: 7086689

Links toward previous steps (curation, corpus...)


Links to Exploration step

PMC:7086689

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Stability and inactivation of SARS coronavirus</title>
<author>
<name sortKey="Rabenau, H F" sort="Rabenau, H F" uniqKey="Rabenau H" first="H. F." last="Rabenau">H. F. Rabenau</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J." last="Cinatl">J. Cinatl</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B." last="Morgenstern">B. Morgenstern</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G." last="Bauer">G. Bauer</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Preiser, W" sort="Preiser, W" uniqKey="Preiser W" first="W." last="Preiser">W. Preiser</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H. W." last="Doerr">H. W. Doerr</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">15118911</idno>
<idno type="pmc">7086689</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086689</idno>
<idno type="RBID">PMC:7086689</idno>
<idno type="doi">10.1007/s00430-004-0219-0</idno>
<date when="2004">2004</date>
<idno type="wicri:Area/Pmc/Corpus">000428</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000428</idno>
<idno type="wicri:Area/Pmc/Curation">000428</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000428</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Stability and inactivation of SARS coronavirus</title>
<author>
<name sortKey="Rabenau, H F" sort="Rabenau, H F" uniqKey="Rabenau H" first="H. F." last="Rabenau">H. F. Rabenau</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Cinatl, J" sort="Cinatl, J" uniqKey="Cinatl J" first="J." last="Cinatl">J. Cinatl</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Morgenstern, B" sort="Morgenstern, B" uniqKey="Morgenstern B" first="B." last="Morgenstern">B. Morgenstern</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Bauer, G" sort="Bauer, G" uniqKey="Bauer G" first="G." last="Bauer">G. Bauer</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Preiser, W" sort="Preiser, W" uniqKey="Preiser W" first="W." last="Preiser">W. Preiser</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H. W." last="Doerr">H. W. Doerr</name>
<affiliation wicri:level="1">
<nlm:aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Medical Microbiology and Immunology</title>
<idno type="ISSN">0300-8584</idno>
<idno type="eISSN">1432-1831</idno>
<imprint>
<date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56°C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60°C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agent’s tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene.</p>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct>
<analytic>
<author>
<name sortKey="Centers" uniqKey="Centers">Centers</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Cinatl" uniqKey="Cinatl">Cinatl</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Cinatl" uniqKey="Cinatl">Cinatl</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Drosten" uniqKey="Drosten">Drosten</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Drosten" uniqKey="Drosten">Drosten</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Marra" uniqKey="Marra">Marra</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Peiris" uniqKey="Peiris">Peiris</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Poutanen" uniqKey="Poutanen">Poutanen</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Reed" uniqKey="Reed">Reed</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Rota" uniqKey="Rota">Rota</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Seto" uniqKey="Seto">Seto</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Sizun" uniqKey="Sizun">Sizun</name>
</author>
</analytic>
</biblStruct>
<biblStruct>
<analytic>
<author>
<name sortKey="Snijder" uniqKey="Snijder">Snijder</name>
</author>
</analytic>
</biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article">
<pmc-dir>properties open_access</pmc-dir>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Med Microbiol Immunol</journal-id>
<journal-id journal-id-type="iso-abbrev">Med. Microbiol. Immunol</journal-id>
<journal-title-group>
<journal-title>Medical Microbiology and Immunology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0300-8584</issn>
<issn pub-type="epub">1432-1831</issn>
<publisher>
<publisher-name>Springer-Verlag</publisher-name>
<publisher-loc>Berlin/Heidelberg</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">15118911</article-id>
<article-id pub-id-type="pmc">7086689</article-id>
<article-id pub-id-type="publisher-id">219</article-id>
<article-id pub-id-type="doi">10.1007/s00430-004-0219-0</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Investigation</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Stability and inactivation of SARS coronavirus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Rabenau</surname>
<given-names>H. F.</given-names>
</name>
<address>
<phone>+49-69-63015312</phone>
<fax>+49-69-630183061</fax>
<email>Rabenau@em.uni-frankfurt.de</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cinatl</surname>
<given-names>J.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morgenstern</surname>
<given-names>B.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bauer</surname>
<given-names>G.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Preiser</surname>
<given-names>W.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Doerr</surname>
<given-names>H. W.</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1">Institute for Medical Virology, Frankfurt am Main University Hospital Medical School, Paul Ehrlich-Strasse 40, 60596 Frankfurt am Main, Germany</aff>
</contrib-group>
<pub-date pub-type="epub">
<day>29</day>
<month>4</month>
<year>2004</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2005</year>
</pub-date>
<volume>194</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>6</lpage>
<history>
<date date-type="received">
<day>25</day>
<month>2</month>
<year>2004</year>
</date>
</history>
<permissions>
<copyright-statement>© Springer-Verlag 2004</copyright-statement>
<license>
<license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>The SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted for most cases, other modes have not been ruled out. Faecal shedding is common and prolonged and has caused an outbreak in Hong Kong. We studied the stability of SARS-CoV under different conditions, both in suspension and dried on surfaces, in comparison with other human-pathogenic viruses, including human coronavirus HCoV-229E. In suspension, HCoV-229E gradually lost its infectivity completely while SARS-CoV retained its infectivity for up to 9 days; in the dried state, survival times were 24 h versus 6 days. Thermal inactivation at 56°C was highly effective in the absence of protein, reducing the virus titre to below detectability; however, the addition of 20% protein exerted a protective effect resulting in residual infectivity. If protein-containing solutions are to be inactivated, heat treatment at 60°C for at least 30 min must be used. Different fixation procedures, e.g. for the preparation of immunofluorescence slides, as well as chemical means of virus inactivation commonly used in hospital and laboratory settings were generally found to be effective. Our investigations confirm that it is possible to care for SARS patients and to conduct laboratory scientific studies on SARS-CoV safely. Nevertheless, the agent’s tenacity is considerably higher than that of HCoV-229E, and should SARS re-emerge, increased efforts need to be devoted to questions of environmental hygiene.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>SARS-associated coronavirus</kwd>
<kwd>Virus infectivity</kwd>
<kwd>Stability</kwd>
<kwd>Thermal inactivation</kwd>
<kwd>Disinfection</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer-Verlag 2004</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000428 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000428 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Pmc
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:7086689
   |texte=   Stability and inactivation of SARS coronavirus
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i   -Sk "pubmed:15118911" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021